SFDA grants marketing authorization for 2 Saudi-developed AI-enabled medical software products
RIYADH — The Saudi Food and Drug Authority (SFDA) has granted marketing authorization for two locally developed, AI-enabled medical software products designed to support dental and ophthalmic diagnosis, "Dental IQ" and "SAARIA." The authorization was granted following a comprehensive regulatory review, including the assessment of technical documentation and clinical evidence to verify the…
RIYADH — The Saudi Food and Drug Authority (SFDA) has given marketing approval to two locally developed AI medical software applications, Dental IQ and SAARIA, designed to aid in dental and ophthalmic diagnoses. The approval follows a thorough examination of technical documentation and clinical evidence to confirm the software’s safety, performance, and efficacy for its intended uses.
Dental IQ employs deep learning algorithms to scrutinize dental X-ray images, aiding in the detection of potential issues like dental caries, periodontal disease, and structural changes affecting teeth and supporting tissues. This tool assists healthcare providers in enhancing diagnostic precision and guiding treatment planning.
Conversely, SAARIA applies AI technologies to analyze retinal images to support the screening of diabetic patients and the early identification of diabetic retinopathy. This aids in identifying patients requiring further specialized ophthalmic assessment, ensuring timely referral and interventions to mitigate disease-related complications.
These two products mark a significant achievement as the first Saudi-developed AI-enabled medical software solutions for dentistry and ophthalmology to receive SFDA approval. Both products are designed as clinical support tools to aid healthcare practitioners in making informed decisions. The AI-driven digital health startups behind the software products participated in the SFDA’s Innovative Medical Devices Pathway, receiving early regulatory guidance and support.
They completed local clinical studies in the Kingdom to verify the software’s performance and committed to post-marketing clinical follow-up plans to monitor real-world performance and ensure safe use.
The SFDA advises against relying solely on the software’s outputs for clinical decisions, as they are meant to assist rather than replace the healthcare professional’s judgment. Healthcare professionals must review and validate the software’s outputs and make appropriate clinical decisions based on the patient’s condition. The approval of these software solutions reflects the SFDA’s dedication to promoting responsible innovation in digital health, supporting the localization of advanced medical technologies, and ensuring timely market access to safe, effective, and high-quality medical devices.
This milestone also aligns with the broader goals of the Health Sector Transformation Program and Saudi Vision 2030.
Written by urgent.news from Saudi Gazette's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
